Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Igor Puzanov*, Jeffrey Sosman, Armando Santoro, Muhammad W. Saif, Laura Goff, Grace K. Dy, Paolo Zucali, Julie A. Means-Powell, Wen Wee Ma, Matteo Simonelli, Robert Martell, Feng Chai, Maria Lamar, Ronald E. Savage, Brian Schwartz, Alex A. Adjei

*Corresponding author for this work

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

Purpose This phase I study evaluated the safety, tolerability, maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of tivantinib combined with sorafenib in patients with advanced solid tumors. Materials and Methods A standard 3+3 dose escalation design was used. At the RP2D, expansion cohorts in 5 tumor types could be enrolled. Pharmacogenetic and pharmacodynamic analysis were performed. Results Eighty-seven patients received the study treatment. The combination had no unexpected toxicities. The most common treatment-related adverse events (AE) were rash (40 %), diarrhea (38 %), and anorexia (33 %). The RP2D was tivantinib 360 mg BID and sorafenib 400 mg BID for all cancer histologies, except in hepatocellular carcinoma (HCC) patients tivantinib was 240 mg BID plus sorafenib 400 mg BID. The overall response rate was 12 % in all patients, 26 % in melanoma, 15 % in renal cell carcinoma (RCC), 10 % in HCC, and 0 % in other patients. Disease control rate (CR, PR and SD ≥8 weeks) was 58 % in all patients, 90 % in RCC, 65 % in HCC, 63 % in melanoma, 40 % in breast cancer, and 8 % in NSCLC patients. Conclusions The combination treatment could be administered at full standard single-agent doses in all patients except those with HCC, where tivantinib was lowered to 240 mg BID. Preliminary evidence of anticancer activity was observed in patients with RCC, HCC, and melanoma, including patients refractory to sorafenib and/or other anti-VEGF pathway therapies. The combination treatment has therapeutic potential in treating a variety of solid tumors.

Original languageEnglish (US)
Pages (from-to)159-168
Number of pages10
JournalInvestigational New Drugs
Volume33
Issue number1
DOIs
StatePublished - Feb 2015

Keywords

  • Advanced tumors
  • MET RTK inhibition
  • Phase I trial
  • Sorafenib
  • Tivantinib
  • VEGF inhibition

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors'. Together they form a unique fingerprint.

  • Cite this

    Puzanov, I., Sosman, J., Santoro, A., Saif, M. W., Goff, L., Dy, G. K., Zucali, P., Means-Powell, J. A., Ma, W. W., Simonelli, M., Martell, R., Chai, F., Lamar, M., Savage, R. E., Schwartz, B., & Adjei, A. A. (2015). Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors. Investigational New Drugs, 33(1), 159-168. https://doi.org/10.1007/s10637-014-0167-5